Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Global Market Report 2025
상품코드:1810996
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
펩티드 치료제 원료의약품 수탁제조 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.4%로 38억 4,000만 달러로 성장합니다. 예측 기간 중 예상되는 성장은 만성질환의 유병률 증가, 표적 생물학적 치료제에 대한 수요 증가, 펩티드 기반 치료제에 대한 선호도 증가, 고순도 제조의 사용 확대, 생명공학 연구개발에 대한 투자 증가로 인해 발생할 것으로 예측됩니다. 이 기간의 주요 동향으로는 고체상 펩티드 합성의 발전, 액상 펩티드 합성의 발전, 하이브리드 합성법의 통합, 정제 기술의 향상, 기술 주도형 연속 제조 공정의 채택 등을 들 수 있습니다.
당뇨병 유병률 증가는 향후 펩티드 치료제 원료의약품 수탁제조 시장의 성장을 촉진할 것으로 예측됩니다. 당뇨병은 인슐린 분비 부족이나 인슐린을 효과적으로 사용할 수 없는 체질로 인한 혈당 상승이 특징인 만성 대사성 질환입니다. 과도한 체지방은 인슐린 저항성을 조장하고 혈당 조절을 방해하기 때문입니다. 펩티드 치료제는 당뇨병 치료에서 인슐린 분비와 혈당 조절을 개선하는 호르몬 모방 약물의 대량 생산을 지원하기 위해 위탁원료의약품 제조를 활용하고 있습니다. 예를 들어 2025년 3월 영국 정부 부서인 Office for Health Improvement and Disparities는 2024년 3월 기준 영국 17세 이상 성인의 2형 당뇨병 유병률이 7.0%로 2023년 3월의 6.8%에서 증가했다고 보고했습니다. 라고 보고했습니다. 따라서 당뇨병 유병률 증가는 펩티드 치료제의 위탁 원료의약품 생산 시장에 박차를 가하고 있습니다.
펩티드 치료제 원료의약품 수탁제조 시장의 주요 기업은 의약품 개발의 복잡성에 대응하고 생산 속도와 품질을 높이기 위해 연속 흐름 합성 플랫폼과 같은 혁신적인 솔루션에 집중하고 있습니다. 이 플랫폼은 반응, 분리, 농축, 결정화 등 여러 단계를 실시간 인라인 모니터링을 통해 하나의 원활한 프로세스로 통합하여 정확하고 비파괴적인 제어와 효율적인 스케일업을 가능하게 합니다. 예를 들어 일본의 연구개발제조수탁기관(CRDMO)인 신크레스트사는 2023년 5월 펩티드 및 뉴클레오티드 원료를 생산하기 위한 연속 흐름 합성 플랫폼을 갖춘 GMP 준수 나루토 공장을 설립했습니다. 이 기술을 통해 100가지 이상의 비천연 아미노산과 고순도 특수 아미타이트를 신속하고 고품질로 제조할 수 있으며, 리드타임과 비용을 크게 줄일 수 있습니다. 이러한 기술 혁신은 확장 가능하고 효율적이며 비용 효율적인 원료의약품 제조를 제공함으로써 첨단 펩티드 치료제에 대한 수요 증가에 대응하고 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 펩티드 치료제 원료의약품 수탁제조 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 펩티드 치료제 원료의약품 수탁제조 시장 : 성장률 분석
세계의 펩티드 치료제 원료의약품 수탁제조 시장 실적 : 규모와 성장, 2019-2024
세계의 펩티드 치료제 원료의약품 수탁제조 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 펩티드 치료제 원료의약품 수탁제조 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 펩티드 치료제 원료의약품 수탁제조 시장 : 사업 규모별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
전임상 또는 임상
상업용
세계의 펩티드 치료제 원료의약품 수탁제조 시장 : 합성 방법에 따르는 실적과 예측, 2019-2024, 2024-2029F, 2034F
비화학 합성
화학 합성
세계의 펩티드 치료제 원료의약품 수탁제조 시장 : 기업 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
대기업
중소기업
세계의 펩티드 치료제 원료의약품 수탁제조 시장 : 서브 세분화, 전임상 또는 임상(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
발견과 전임상 개발
단계 II 또는 단계 III 제조
단계 I 제조
세계의 펩티드 치료제 원료의약품 수탁제조 시장 : 서브 세분화, 상업용(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
상업 규모의 적정 제조 규범(GMP) 제조
기술 이전과 스케일업
수명주기관리 또는 프로세스 최적화
제7장 지역별·국가별 분석
세계의 펩티드 치료제 원료의약품 수탁제조 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 펩티드 치료제 원료의약품 수탁제조 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
펩티드 치료제 원료의약품 수탁제조 시장 : 경쟁 구도
펩티드 치료제 원료의약품 수탁제조 시장 : 기업 개요
Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
Lonza Group AG. Overview, Products and Services, Strategy and Financial Analysis
WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
Cambrex Corporation Overview, Products and Services, Strategy and Financial Analysis
ChemPartner Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
GenScript Biotech Corporation
Bachem Group
CordenPharma International GmbH
Syngene International Limited
Ambiopharm Inc.
CPC Scientific Inc.
ScinoPharm Taiwan Ltd.
Hybio Pharmaceutical Co. Ltd.
CEM Corporation
CSBio Company Inc.
Senn Chemicals AG.
AnaSpec Inc.
LifeTein LLC
Apex Biotechnology Corp.
BCN Peptides S.A.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
펩티드 치료제 원료의약품 수탁제조 시장 2029 : 새로운 기회를 제공하는 국가
펩티드 치료제 원료의약품 수탁제조 시장 2029 : 새로운 기회를 제공하는 부문
펩티드 치료제 원료의약품 수탁제조 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Peptide therapeutics contract active pharmaceutical ingredient manufacturing involves outsourcing the production of peptide-based active pharmaceutical ingredients to specialized third-party manufacturers who operate under stringent regulatory standards. These manufacturers provide services such as custom synthesis, purification, and GMP-grade production to support both clinical trials and commercial supply of peptide therapeutics.
The primary scales of operation in peptide therapeutics contract API manufacturing include preclinical or clinical and commercial stages. The preclinical or clinical phase covers early drug development, involving laboratory research and human trials to assess the safety and effectiveness of peptide drugs. Various synthesis methods are employed, including both chemical and non-chemical approaches, catering to different types of enterprises, from large corporations to small and medium-sized businesses.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market research report is one of a series of new reports from The Business Research Company that provides peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market statistics, including the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing industry's global market size, regional shares, competitors with the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market share, detailed peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market. This peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market size has grown strongly in recent years. It will grow from $2.68 billion in 2024 to $2.89 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth during the historic period can be attributed to an expanding pipeline of peptide therapeutics, a rising global focus on personalized medicine, increased demand fueled by GLP-1 blockbuster drugs, heightened emphasis on sustainable manufacturing, and growing approval rates of peptide therapeutics.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market size is expected to see strong growth in the next few years. It will grow to $3.84 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth anticipated in the forecast period is driven by the increasing prevalence of chronic diseases, rising demand for targeted biologic therapies, a growing preference for peptide-based therapeutics, expanded use of high-purity manufacturing, and increased investment in biotech research and development. Key trends during this period include advancements in solid-phase peptide synthesis, progress in liquid-phase peptide synthesis, the integration of hybrid synthesis methods, improvements in purification technologies, and the adoption of technology-driven continuous manufacturing processes.
The increasing prevalence of diabetes is expected to drive growth in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market moving forward. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels caused by insufficient insulin production or the body's inability to use insulin effectively. This rise in diabetes cases is mainly driven by increasing obesity rates, as excess body fat contributes to insulin resistance and impairs blood sugar regulation. Peptide therapeutics utilize contract API manufacturing to support large-scale production of hormone-mimicking drugs that improve insulin secretion and glucose control in diabetes treatment. For example, in March 2025, the Office for Health Improvement and Disparities, a UK government department, reported that the prevalence of type 2 diabetes among adults aged 17 and older in England was 7.0% as of March 2024, up from 6.8% in March 2023. Hence, the growing prevalence of diabetes is fueling the peptide therapeutics contract API manufacturing market.
Key players in the peptide therapeutics contract API manufacturing market are focusing on innovative solutions like the continuous flow synthesis platform to enhance production speed and quality while managing increasing drug development complexity. This platform combines multiple stages-including reaction, separation, concentration, and crystallization-into a single, seamless process with real-time in-line monitoring, enabling precise, non-destructive control and efficient scale-up. For instance, in May 2023, SynCrest Inc., a Japan-based contract research, development, and manufacturing organization (CRDMO), launched its GMP-compliant Naruto Plant equipped with a continuous flow synthesis platform for producing peptide and nucleotide APIs. This technology facilitates rapid, high-quality manufacturing of over 100 types of non-natural amino acids and high-purity special amidites, substantially reducing lead times and costs. Such innovations meet growing demand for advanced peptide therapeutics by offering scalable, efficient, and cost-effective API manufacturing.
In December 2024, Novo Holdings A/S, a Denmark-based asset management firm, acquired Catalent Inc. for $16.5 billion. Through this acquisition, Novo Holdings aims to enhance the development and delivery of transformative therapies, improve patient outcomes worldwide, and create sustainable value in life sciences through active ownership. Catalent Inc., headquartered in the US, is a pharmaceutical company specializing in contract manufacturing services for active pharmaceutical ingredients, including peptide therapeutic APIs.
Major players in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market are Thermo Fisher Scientific Inc., Lonza Group AG., WuXi AppTec Co. Ltd., Cambrex Corporation, ChemPartner, GenScript Biotech Corporation, Bachem Group, CordenPharma International GmbH, Syngene International Limited, Ambiopharm Inc., CPC Scientific Inc., ScinoPharm Taiwan Ltd., Hybio Pharmaceutical Co. Ltd., CEM Corporation, CSBio Company Inc., Senn Chemicals AG., AnaSpec Inc., LifeTein LLC, Apex Biotechnology Corp., and BCN Peptides S.A.
North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market includes revenues earned by entities through custom peptide synthesis, process development and optimization, and analytical development and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Scale Of Operation: Preclinical Or Clinical; Commercial
2) By Synthesis Method: Non Chemical Synthesis; Chemical Synthesis
3) By Enterprise Type: Large Enterprise; Small And Medium Enterprises
Subsegments:
1) By Preclinical Or Clinical: Discovery And Preclinical Development; Phase II Or III Manufacturing; Phase I Manufacturing
2) By Commercial: Commercial-Scale Good Manufacturing Practice Manufacturing; Tech Transfer And Scale-up; Lifecycle Management Or Process Optimization
3. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Trends And Strategies
4. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Growth Analysis And Strategic Analysis Framework
5.1. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Growth Rate Analysis
5.4. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Total Addressable Market (TAM)
6.1. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Preclinical Or Clinical
Commercial
6.2. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Non Chemical Synthesis
Chemical Synthesis
6.3. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Large Enterprise
Small And Medium Enterprises
6.4. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Sub-Segmentation Of Preclinical Or Clinical, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Discovery And Preclinical Development
Phase II Or III Manufacturing
Phase I Manufacturing
6.5. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Sub-Segmentation Of Commercial, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Commercial-Scale Good Manufacturing Practice Manufacturing
Tech Transfer And Scale-up
Lifecycle Management Or Process Optimization
7. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Regional And Country Analysis
7.1. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
9.1. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
9.2. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
10.1. India Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
11.1. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
11.2. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
12.1. Australia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
13.1. Indonesia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
14.1. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
14.2. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
15.1. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
15.2. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
16.1. UK Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
18.1. France Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
21.1. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
21.2. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
22.1. Russia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
23.1. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
23.2. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
24.1. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
24.2. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
26.1. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
26.2. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
27.1. Brazil Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
28.1. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
28.2. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market
29.1. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview
29.2. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Scale Of Operation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Synthesis Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market, Segmentation By Enterprise Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Competitive Landscape And Company Profiles
